The European Institute of Oncology (IEO) is a Comprehensive Cancer Center, with a strong commitment to excellence in clinical care as well as basic and applied research. It is the largest Cancer Center in Northern Italy, serving more than 30,000 patients per year and its research department is part of the EU-LIFE alliance, which includes 15 European leading research centers in life sciences.
The Department of Experimental Oncology at IEO currently hosts 23 independent research groups supported by 11 technological units and focusing on understanding cellular and molecular mechanisms of tumor development, dissemination and resistance to therapy. Specific research areas include chromatin and transcriptional regulation, genome integrity, control of cell cycle and division, signaling and endocytosis, tumor tissue organization and evolution, microbiome and immunity.
The IEO is now launching a novel Immuno-Oncology Program with the objective to investigate immune-mediated mechanisms in human cancers in order to eventually exploit them for therapy.
In the context of this program, we are now looking for an outstanding group leader in human cellular and molecular immunology. We will consider applications at all career stages, including tenure track and tenured positions. We strongly encourage the application of scientists with a demonstrated track record of independent research activity.
If you would like to informally discuss this position, please contact the head of Department, Professor Pier Giuseppe Pelicci (email@example.com).
These informal enquiries will be treated in strict confidence.
The applications must include:
- Complete CV.
- Concise description of previous achievements and current research interests.
- Brief (4 pages max) outline of future research plans.
- Name and e-mail address of at least three referees.
Applications should be submitted by e-mail to firstname.lastname@example.org
The closing date for applications is November 1st, 2021.
IEO is an equal opportunity employer committed to excellence through diversity.